Hansa Biopharma (HNSA) Q3 2026 earnings summary

Executive summary

• Completed the €115m SERB Idefirix licensing transaction for Europe and MENA; the €110m upfront payment received in July strengthened liquidity and advanced the transition of European responsibilities.

• Q3 priorities included US launch preparation, presentation of ConfIdeS and PAES data, and submission of an FDA IND for HNSA-5487 in GBS.

Financial highlights

• Q3 revenue was SEK 143.0m versus SEK 30.8m in Q3 2025: SEK 121.6m license revenue, SEK 20.8m supply and service revenue, and SEK 0.6m contract revenue.

• Q3 operating loss was SEK 138.6m versus SEK 147.6m; net loss was SEK 178.5m versus SEK 148.3m, reflecting higher financial expense and the SERB inventor compensation charge.

• Operating cash flow was SEK 964.4m versus SEK -106.9m; cash and equivalents were SEK 1,337.2m at September 30, 2026.

Outlook and guidance

• Idefirix PDUFA date is December 19, 2026; US commercialization and product availability are planned for Q1 2027, subject to FDA approval.

• EMA filing to convert Idefirix to full marketing authorization is planned for Q4 2026; SERB owes a further €5m upon EMA acceptance.

• First patient enrollment in the 16-patient HNSA-5487 GBS Phase 2a study is anticipated in Q1 2027; a pivotal Phase 3 plan depends on Phase 2a results.

• Current cash is expected to support operations well into 2028.